CR8942A - Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos. - Google Patents
Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos.Info
- Publication number
- CR8942A CR8942A CR8942A CR8942A CR8942A CR 8942 A CR8942 A CR 8942A CR 8942 A CR8942 A CR 8942A CR 8942 A CR8942 A CR 8942A CR 8942 A CR8942 A CR 8942A
- Authority
- CR
- Costa Rica
- Prior art keywords
- growth hormone
- human growth
- glicerol
- ramified
- conjugates
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 6
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 6
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
- 230000006320 pegylation Effects 0.000 abstract 2
- 206010012559 Developmental delay Diseases 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60594504P | 2004-08-31 | 2004-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8942A true CR8942A (es) | 2007-08-16 |
Family
ID=35708806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8942A CR8942A (es) | 2004-08-31 | 2007-02-26 | Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos. |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1789092A2 (ko) |
JP (1) | JP2008511610A (ko) |
KR (1) | KR20070042567A (ko) |
CN (1) | CN101010105A (ko) |
AP (1) | AP2007003919A0 (ko) |
AR (1) | AR050851A1 (ko) |
AU (1) | AU2005278903A1 (ko) |
BR (1) | BRPI0515118A (ko) |
CA (1) | CA2577999A1 (ko) |
CR (1) | CR8942A (ko) |
EA (1) | EA200700380A1 (ko) |
EC (1) | ECSP077281A (ko) |
GT (1) | GT200500235A (ko) |
IL (1) | IL181085A0 (ko) |
MA (1) | MA28908B1 (ko) |
MX (1) | MX2007002441A (ko) |
NL (1) | NL1029828C2 (ko) |
NO (1) | NO20071322L (ko) |
PE (1) | PE20060654A1 (ko) |
TN (1) | TNSN07078A1 (ko) |
TW (1) | TW200621291A (ko) |
UY (1) | UY29088A1 (ko) |
WO (1) | WO2006024953A2 (ko) |
ZA (1) | ZA200701802B (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
BR9812267B1 (pt) | 1997-07-14 | 2013-11-26 | Hormônio de crescimento recombinante. | |
EP1144613B2 (en) | 1999-01-14 | 2020-05-06 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
EP1834963A1 (en) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
MX2008014358A (es) * | 2006-05-12 | 2008-11-24 | Dong A Pharm Co Ltd | Conjugado de polietilenglicol-interferon alfa. |
JP2008069073A (ja) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | ラクトフェリン複合体及びその製造方法 |
KR101079993B1 (ko) | 2006-11-17 | 2011-11-04 | 동아제약주식회사 | 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체 |
CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
WO2010011096A2 (en) * | 2008-07-23 | 2010-01-28 | Hanmi Pharmaceutical Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
AU2009276458B2 (en) | 2008-07-31 | 2014-06-19 | Pharmaessentia Corp. | Peptide-polymer conjugates |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
PT2355853T (pt) * | 2008-10-10 | 2017-03-15 | Polyactiva Pty Ltd | Conjugados polímero biodegradável ¿ unidade bioativa |
SI2340271T1 (sl) | 2008-10-10 | 2019-08-30 | Polyactiva Pty Ltd. | Konjugati polimer-bioaktivnega sredstva |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
JP6086528B2 (ja) | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有する成長ホルモン |
CN101831067A (zh) * | 2010-05-31 | 2010-09-15 | 王二新 | 聚乙二醇脂类缀合物及其在制备药物中的应用 |
EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
CN102367290B (zh) * | 2011-04-26 | 2013-05-08 | 厦门赛诺邦格生物科技有限公司 | 链官能化的多级支化聚乙二醇及其合成方法 |
WO2014110867A1 (zh) * | 2013-01-17 | 2014-07-24 | 厦门赛诺邦格生物科技有限公司 | 一种单一官能化的支化聚乙二醇及其修饰的生物相关物质 |
CN104877127B (zh) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质 |
SI3215193T1 (sl) | 2014-11-06 | 2024-02-29 | Pharmaessentia Corporation | Dozirna shema za pegiliran interferon |
JP7227633B2 (ja) * | 2017-12-29 | 2023-02-22 | エフ. ホフマン-ラ ロシュ エージー. | Peg化タンパク質組成物を提供するための方法 |
EP3731872B1 (en) | 2017-12-29 | 2021-11-24 | F. Hoffmann-La Roche AG | Process for providing pegylated protein composition |
JP7137625B2 (ja) * | 2017-12-29 | 2022-09-14 | エフ.ホフマン-ラ ロシュ アーゲー | Peg化タンパク質組成物を提供するための方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
JP3092531B2 (ja) * | 1996-11-05 | 2000-09-25 | 日本油脂株式会社 | コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法 |
BR9812267B1 (pt) * | 1997-07-14 | 2013-11-26 | Hormônio de crescimento recombinante. | |
JP3921781B2 (ja) * | 1998-02-12 | 2007-05-30 | 日本油脂株式会社 | カルボキシル基含有ポリオキシアルキレン化合物 |
EP1144613B2 (en) * | 1999-01-14 | 2020-05-06 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
IL162031A0 (en) * | 2001-11-20 | 2005-11-20 | Pharmacia Corp | Chemically-modified human growth hormone conjugates |
AP2005003246A0 (en) * | 2002-09-09 | 2005-03-31 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanals |
JP4412461B2 (ja) * | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
WO2004060406A2 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
TR201907313T4 (tr) * | 2003-05-23 | 2019-06-21 | Nektar Therapeutics | İki PEG zinciri içeren PEG türevleri. |
-
2005
- 2005-08-25 EA EA200700380A patent/EA200700380A1/ru unknown
- 2005-08-25 CA CA002577999A patent/CA2577999A1/en not_active Abandoned
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/zh active Pending
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/es unknown
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/pt not_active IP Right Cessation
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/xx unknown
- 2005-08-25 EP EP05784225A patent/EP1789092A2/en not_active Withdrawn
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/en active Application Filing
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/ko not_active Application Discontinuation
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/ja active Pending
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/es not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/es unknown
- 2005-08-29 UY UY29088A patent/UY29088A1/es not_active Application Discontinuation
- 2005-08-30 NL NL1029828A patent/NL1029828C2/nl not_active IP Right Cessation
- 2005-08-30 TW TW094129583A patent/TW200621291A/zh unknown
- 2005-08-30 GT GT200500235A patent/GT200500235A/es unknown
-
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/es not_active Application Discontinuation
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/fr unknown
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/es unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/fr unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/xx unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ECSP077281A (es) | 2007-03-29 |
MX2007002441A (es) | 2007-05-04 |
IL181085A0 (en) | 2007-07-04 |
EA200700380A1 (ru) | 2007-10-26 |
GT200500235A (es) | 2006-03-21 |
ZA200701802B (en) | 2008-08-27 |
NL1029828C2 (nl) | 2006-10-20 |
NL1029828A1 (nl) | 2006-03-01 |
WO2006024953A3 (en) | 2007-01-18 |
JP2008511610A (ja) | 2008-04-17 |
CA2577999A1 (en) | 2006-03-09 |
NO20071322L (no) | 2007-05-29 |
KR20070042567A (ko) | 2007-04-23 |
EP1789092A2 (en) | 2007-05-30 |
PE20060654A1 (es) | 2006-08-12 |
MA28908B1 (fr) | 2007-10-01 |
BRPI0515118A (pt) | 2008-07-01 |
AP2007003919A0 (en) | 2007-02-28 |
AU2005278903A1 (en) | 2006-03-09 |
TW200621291A (en) | 2006-07-01 |
CN101010105A (zh) | 2007-08-01 |
WO2006024953A2 (en) | 2006-03-09 |
AR050851A1 (es) | 2006-11-29 |
UY29088A1 (es) | 2006-03-31 |
TNSN07078A1 (fr) | 2008-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8942A (es) | Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos. | |
AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
BRPI0513508A (pt) | conjugados de insulina-oligÈmero, formulações e usos desses | |
BR0313343A (pt) | Uso de uma mistura de agentes permeantes, soluções para aplicação ungueal e periungueal e uso de uma solução para aplicação ungueal e periungueal | |
NZ591261A (en) | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin | |
CO6501124A2 (es) | Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas | |
PE20090605A1 (es) | Composiciones de fenilalanina amoniaco-liasa procariotica y metodos del tratamiento del cancer usando composiciones de la misma | |
CR11648A (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas | |
PE20080339A1 (es) | Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento | |
CY1111177T1 (el) | Ενωση φαινοθειαζινιου για επουλωση τραυματων | |
AR053651A1 (es) | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama | |
CR8722A (es) | Composiciones de metadona para uso topico y metodos para el uso de las mismas | |
PA8594801A1 (es) | Formulaciones farmaceuticas liquidas de palanosetron | |
AR051765A1 (es) | Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas | |
CL2012003038A1 (es) | Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia. | |
EA201370006A1 (ru) | Местная фармацевтическая композиция, содержащая флурбипрофен | |
CY1109843T1 (el) | Αναλογα της βιταμινης d | |
DK1608346T3 (da) | Lægemiddeltilförselssammensætninger af alfa-hydroxysyreester og fremgangsmåder til anvendelse heraf | |
PE20121799A1 (es) | Polipeptidos de somatotropina porcina modificados y sus usos | |
CO6280503A2 (es) | Conjugados de neurturina novedosas para uso farmaceutico | |
AR077347A1 (es) | Mejoramientos en composiciones farmaceuticas y relacionados con ellas | |
BRPI0518619A2 (pt) | mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica | |
PE20070430A1 (es) | Composiciones topicas que comprenden o-desmetilvenlafaxina (odv) | |
BR112012015437A2 (pt) | composição tópica substancialmente anidra de armazenamento estável | |
ECSP088242A (es) | Combinaciones que comprenden dmxaa para el tratamiento de cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |